Phospholipase A2 regulates eicosanoid class switching during inflammasome activation.

Area of Science:

• Immunology
• Molecular Biology
• Lipid Mediator Synthesis

Background:

• Inflammation initiation and resolution are linked processes.
• Lipoxins (LX) are proresolution lipid mediators that resolve inflammation by influencing immune cell recruitment via the LXA4 receptor (ALX).
• Current understanding of lipoxin (LX) biosynthesis is incomplete, lacking clarity on efficient precursor formation and direct generation post-receptor activation.

Purpose of the Study:

• To elucidate the mechanism of lipoxin (LX) generation within a single immune cell.
• To investigate the role of sequential Toll-like receptor 4 (TLR4) and P2X7 receptor activation in lipoxin (LX) biosynthesis.
• To identify the specific pathways and precursors involved in receptor-mediated lipoxin (LX) production.

Main Methods:

• Investigated lipoxin (LX) generation in macrophages following sequential activation of Toll-like receptor 4 (TLR4) and P2X7 receptors.
• Measured accumulation of 15-hydroxyeicosatetraenoic acid (15-HETE) precursor within membrane phospholipids after TLR4 activation.
• Assessed the role of group IVA cytosolic phospholipase A2 and 5-lipoxygenase in converting 15-HETE to lipoxins (LX) after P2X7 activation.

Main Results:

• Demonstrated that sequential TLR4 and P2X7 receptor activation in macrophages leads to lipoxin (LX) generation.
• Identified 15-hydroxyeicosatetraenoic acid (15-HETE) as a stored precursor within membrane phospholipids, whose release is triggered by P2X7 activation.
• Showed that aspirin (ASA) treatment can enhance the accumulation of the 15-HETE precursor.

Conclusions:

• Macrophages can store proresolving lipid precursors (15-HETE) and release them for bioactive conversion, similar to IL-1 cytokine maturation.
• This pathway highlights receptor-specific and combinatorial control over eicosanoid biosynthesis, balancing pro- and anti-inflammatory signals.
• Findings offer potential strategies to modulate inflammatory responses by targeting specific lipid mediator pathways without broadly inhibiting eicosanoid synthesis.